Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$22.87 USD
+1.36 (6.32%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $22.91 +0.04 (0.17%) 5:08 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 241 - 260 ( 291 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Naming Next Dev Candidate by YE, Lead Program in Clinic Mid-2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q19: Modular Therapy May Unlock Opportunities. ''2001 IND Filing On Track
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q Financials; NTLA-2001 IND Filing Guided for Mid-2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Update - Progress Is Being Made, NTLA-2001 IND Filing In Mid-2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fully Valued Ahead of FIH Studies. Initiating at Neutral. $16 PT.
Provider: Roth Capital Partners, Inc.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
UPGRADING to OP; ATTR IND in 2020; Cell Therapy Program at the Heels
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
FY18; Quiet Year Ahead for NTLA as First IND Submission Targeted for 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL as IND for Lead ATTR Candidate Pushed Back into 2020
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Intellia Therapeutics, Inc.
Industry: Unclassified
Potential Headline Risk with Pending Court Decision, LT Impact Likely Minimal
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D